Sun Pharma has introduced LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for severe alopecia areata after settling a patent dispute with Incyte. Approved by the FDA and backed by strong clinical ...

Although anti-PD-1 therapy, alone or in combination with an anti-CTLA-4 agent, has become the first-line standard of care for ...

Shares of HDFC Life Insurance, HDB Financial, ICICI Lombard, Just Dial will remain in focus as companies will declare Q1 ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

India VIX, the fear gauge, eased 3 percent which suggests that there are little-to-no signs of panic-driven exits.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The Indian equity indices, the Sensex and the Nifty, are expected to open on a flat-to-higher note on Tuesday, following ...